Cargando…

RNA m(6)A Methylation Regulators Subclassify Luminal Subtype in Breast Cancer

RNA N(6)-methyladenosine (m(6)A) methylation is the most prevalent epitranscriptomic modification in mammals, with a complex and fine-tuning regulatory system. Recent studies have illuminated the potential of m(6)A regulators in clinical applications including diagnosis, therapeutics, and prognosis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Lin, Wu, Shuangling, Ma, Chunhui, Song, Shuhui, Jin, Feng, Niu, Yamei, Tong, Wei-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878528/ https://www.ncbi.nlm.nih.gov/pubmed/33585234 http://dx.doi.org/10.3389/fonc.2020.611191

Ejemplares similares

Region-specific RNA m(6)A methylation represents a new layer of control in the gene regulatory network in the mouse brain
por: Chang, Mengqi, et al.
Publicado: (2017)

Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2022)

RNA m(6)A methylation participates in regulation of postnatal development of the mouse cerebellum
por: Ma, Chunhui, et al.
Publicado: (2018)

Artificial Intelligence Role in Subclassifying Cytology of Thyroid Follicular Neoplasm
por: Aly Alabrak, Mona Mohamed, et al.
Publicado: (2023)

Association of Genetic Variants With Migraine Subclassified by Clinical Symptoms in Adult Females
por: Kossowsky, Joe, et al.
Publicado: (2021)

Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development
por: Li, Ruo Qi, et al.
Publicado: (2022)

Reliability of the ISAKOS Modification to Subclassify Rockwood Type III Acromioclavicular Joint Injuries
por: Velasquez Garcia, Ausberto, et al.
Publicado: (2022)

310. Yogurt Intake and Colorectal Cancer Incidence Subclassified by Bifidobacterium Status in Tumor
por: Ugai, Satoko, et al.
Publicado: (2023)

Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype
por: Wang, Yunmei, et al.
Publicado: (2020)

Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers
por: Liu, Xiaonan, et al.
Publicado: (2021)

Path to Clonal Theranostics in Luminal Breast Cancers
por: Hajjaji, Nawale, et al.
Publicado: (2022)

Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
por: Diana, Anna, et al.
Publicado: (2022)

Development and validation of an ultrasound-based radiomics nomogram for predicting the luminal from non-luminal type in patients with breast carcinoma
por: Wu, Jiangfeng, et al.
Publicado: (2022)

Malignant Evaluation and Clinical Prognostic Values of m6A RNA Methylation Regulators in Glioblastoma
por: Du, Jianyang, et al.
Publicado: (2020)

Emerging Roles of m(6)A RNA Methylation Regulators in Gynecological Cancer
por: Huang, Wanjun, et al.
Publicado: (2022)

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
por: Whitworth, Pat, et al.
Publicado: (2016)

Expression and significance of m6A-RNA-methylation in oral cancer and precancerous lesion
por: Qin, Zhiming, et al.
Publicado: (2023)

FTO promotes liver inflammation by suppressing m6A mRNA methylation of IL-17RA
por: Gan, Xiaojie, et al.
Publicado: (2022)

RNA atlas and competing endogenous RNA regulation in tissue-derived exosomes from luminal B and triple-negative breast cancer patients
por: Wang, Ji, et al.
Publicado: (2023)

Comprehensive proteome, phosphoproteome and kinome characterization of luminal A breast cancer
por: Yang, Ganglong, et al.
Publicado: (2023)

MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers
por: Sadeghian, Dorsay, et al.
Publicado: (2022)

m(6)A RNA Methylation Regulators Impact Prognosis and Tumor Microenvironment in Renal Papillary Cell Carcinoma
por: Chen, Lianze, et al.
Publicado: (2021)

Role of N6-Methyladenosine (m(6)A) Methylation Regulators in Hepatocellular Carcinoma
por: Qu, Nanfang, et al.
Publicado: (2021)

m(6)A Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes
por: Chen, Jiawei, et al.
Publicado: (2021)

Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Should a Multigene Signature be Used in all Luminal Early Breast Cancers
por: Hajjaji, Nawale, et al.
Publicado: (2019)

Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy
por: Liu, Yushi, et al.
Publicado: (2022)

M6A RNA Methylation Regulator HNRNPC Contributes to Tumorigenesis and Predicts Prognosis in Glioblastoma Multiforme
por: Wang, Li-chong, et al.
Publicado: (2020)

Comprehensive Analysis of m6A RNA Methylation Regulators in the Prognosis and Immune Microenvironment of Multiple Myeloma
por: Liu, Rui, et al.
Publicado: (2021)

RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer
por: Wang, Yan, et al.
Publicado: (2023)

SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer
por: Huo, Qin, et al.
Publicado: (2020)

Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects
por: Albert, Veruschka, et al.
Publicado: (2022)

Identification of a Novel Luminal Molecular Subtype of Breast Cancer
por: Dvorkin-Gheva, Anna, et al.
Publicado: (2014)

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
por: Gong, Yajie, et al.
Publicado: (2020)

Effect of m(6)A RNA Methylation Regulators on Malignant Progression and Prognosis in Renal Clear Cell Carcinoma
por: Wang, Jiawu, et al.
Publicado: (2020)

N(6)-methyl-adenosine (m(6)A) in RNA: An Old Modification with A Novel Epigenetic Function
por: Niu, Yamei, et al.
Publicado: (2013)

Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study
por: Liu, Qiuyue, et al.
Publicado: (2022)

N(6)-Methyladenosine RNA Demethylase FTO Promotes Gastric Cancer Metastasis by Down-Regulating the m6A Methylation of ITGB1
por: Wang, Duo, et al.
Publicado: (2021)

m(6)A RNA Methylation Regulators Contribute to Malignant Progression and Have Clinical Prognostic Impact in Gastric Cancer
por: Su, Yunshu, et al.
Publicado: (2019)

Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer
por: Xu, Zhiyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mg24q4p7v9uqhmatgb714jhabr